Patrick Trucchio
Recent Articles
New Therapy for AATD Could be Best in Class 04/08/2025
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
PDUFA Date Nearing for New PSVT Drug 03/19/2025
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report.
Analyst Says CA Pharma Underappreciated by Investors 07/23/2024
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors.
Due to permission requirements, not all quotes are shown.
